It will almost certainly be priced at a premium over Wegovy, yes. The industry expectation is somewhere in the $1,500-2,000/month range, compared to Wegovy's ~$1,350 list price.

However, Novo is likely to position CagriSema as a second-line option for patients who haven't achieved sufficient weight loss on semaglutide alone, or as a first-line option for patients with higher BMI who need more aggressive treatment. That justifies the premium from a health-economic perspective if you can demonstrate superior outcomes.

The real competition isn't pricing against Wegovy — it's pricing against Zepbound (tirzepatide). If CagriSema can match or beat tirzepatide's efficacy, Novo can argue for price parity with Zepbound (~$1,060 list).

Something that's been underappreciated: the REDEFINE-6 trial is studying CagriSema specifically for weight loss maintenance after an initial treatment period. This is arguably more important than the acute weight loss data.

We know from STEP-1 extension data that ~2/3 of weight is regained within a year of stopping semaglutide. If CagriSema shows better weight maintenance — either during active treatment or after step-down — that could be its most compelling differentiator.

The amylin pathway's role in long-term energy homeostasis and body weight "set point" regulation is still poorly understood. It's possible that dual-pathway suppression creates more durable metabolic adaptation than GLP-1 alone.

Honestly, what excites me most about CagriSema is that it represents a different approach than just "add more incretin receptors." The obesity pipeline has been very incretin-centric (GLP-1, GIP, glucagon), and while those results are fantastic, having a mechanistically distinct combination (amylin + GLP-1) adds diversity to the treatment landscape.

Different patients may respond differently to different mechanisms. Having amylin-based options alongside incretin-based options gives clinicians more tools to personalize treatment. That's ultimately good for patients even if the headline weight loss numbers are similar.

Well said. Competition in this space is good for everyone. We're moving from "one GLP-1 fits all" to a toolkit of mechanistically diverse options. Worth noting that Novo also has amycretin in early development — a single molecule with both GLP-1 and amylin activity (rather than combining two separate drugs). That could be the next evolution beyond CagriSema.

The pace of innovation in this field is genuinely remarkable. Five years ago, we had liraglutide and that was about it. Now we're debating the merits of triple agonists vs. amylin combinations. Great time to be following obesity pharmacology.